Pyroscint (99mTc-PYP)
Tc-MR-9

Active substance
- Sodium Pyrophosphate Decahydrate

Indications
- bone scintigraphy, especially
  - primer bone tumours imaging
  - bone metastases of other tumours (e.g. prostate, breast, lung cancer)
  - osteomyelitis
  - metabolic bone disease
  - Paget's disease
- blood pool scintigraphy (in vivo or in vivo/in vitro) labelled red blood cells:
  - angioscintigraphy for:
    - evaluation of ventricular ejection fraction
    - evaluation of global and regional cardiac wall motion
    - myocardial phase imaging
    - organ perfusion and vascular abnormalities
    - diagnosis and localisation of occult gastro-intestinal bleeding
- determination of blood volume
- spleen scintigraphy
  (for detailed information see SmPC)

Excipients
- Stannous(II) chloride dihydrate
- Sodium acetate trihydrate
- Ascorbic acid

Dose for adults
- Suggested dose ranges are different according to the type of investigation
  (for detailed information see SmPC)

Labelling activity
- 3.0 - 6.0 GBq

Labelling volume
- Bone imaging: 185-555 MBq
- Blood pool imaging: 555-740 MBq
- Cardiac imaging: 370-555 MBq
  (for detailed information see SmPC)

Storage of cold kit
- 24 months from date of manufacturing, below 25°C protected from light

Storage of labelled compound
- 6 hrs below 25°C

Package size
- 6 vials

Registration numbers
- Hungary: OGYI-T-8817/01

Marketing Authorization Holder
- Medi-Radiopharma Co., Ltd.
  2030 Érd, Szamos utca 10-12.
  Hungary